Additional file 2: Table S2. A) Peptides with a statistically significant (p < 0.05) urinary abundance (m/z area) according to the pT. B) Peptides with a statistical significant (p < 0.05) urinary abundance (m/z area) compared to CTRLs and at different pT (1 = pT1a; 2 = pT1b; 3 = pT2a and 4 = pT > 2b). Up/down refer to the over/under representation of the peptide in ccRCC patients compared to control subject
Figure S1. Flow chart illustrating the sample inclusion/exclusion process in malignant cores. A) 5mC...
Distribution of 5hmC scores by clinicopathological parameters and BCR status in ERG− PC. ERG− subset...
PyMT activity comparison with tumor histology, molecular subtype, and metastasis. a Western blot qua...
Additional file 3: Table S3. A) Peptides with a statistical significant (p < 0.05) urinary abundan...
Additional file 1: Table S1. Peptides with a statistically significant (p < 0.05) urinary abundanc...
Additional file 4: Table S4. Peptides with a statistically significant (p > 0.05) urinary abundanc...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Additional file 2: Table S2 Average Chi Square value per gene symbol for ovarian cancer versus norma...
Additional file 7: Figure S2. Performance of the urinary proteome profiling workflow in peptide leve...
Figure S2. Flow chart illustrating the sample inclusion/exclusion process in NM cores. A) 5mC score....
Figure S4. a) Contingency table showing the frequency distribution of CCDC6 intensity IHC staining v...
Additional file 3. Table S2. The number of identified and quantified proteins in individual samples ...
Distribution of 5hmC scores by clinicopathological parameters and BCR in the full PC patient set. Fu...
Additional file 5: Table S5. Identification of MALDI signals varied according to tumour size, pT o...
Figure S1. Flow chart illustrating the sample inclusion/exclusion process in malignant cores. A) 5mC...
Distribution of 5hmC scores by clinicopathological parameters and BCR status in ERG− PC. ERG− subset...
PyMT activity comparison with tumor histology, molecular subtype, and metastasis. a Western blot qua...
Additional file 3: Table S3. A) Peptides with a statistical significant (p < 0.05) urinary abundan...
Additional file 1: Table S1. Peptides with a statistically significant (p < 0.05) urinary abundanc...
Additional file 4: Table S4. Peptides with a statistically significant (p > 0.05) urinary abundanc...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Background: Several promising biomarkers have been found for RCC, but none of them has been used in ...
Additional file 2: Table S2 Average Chi Square value per gene symbol for ovarian cancer versus norma...
Additional file 7: Figure S2. Performance of the urinary proteome profiling workflow in peptide leve...
Figure S2. Flow chart illustrating the sample inclusion/exclusion process in NM cores. A) 5mC score....
Figure S4. a) Contingency table showing the frequency distribution of CCDC6 intensity IHC staining v...
Additional file 3. Table S2. The number of identified and quantified proteins in individual samples ...
Distribution of 5hmC scores by clinicopathological parameters and BCR in the full PC patient set. Fu...
Additional file 5: Table S5. Identification of MALDI signals varied according to tumour size, pT o...
Figure S1. Flow chart illustrating the sample inclusion/exclusion process in malignant cores. A) 5mC...
Distribution of 5hmC scores by clinicopathological parameters and BCR status in ERG− PC. ERG− subset...
PyMT activity comparison with tumor histology, molecular subtype, and metastasis. a Western blot qua...